214 related articles for article (PubMed ID: 9870321)
1. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.
Kundu SK; Dupuis M; Sette A; Celis E; Dorner F; Eibl M; Merigan TC
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1669-78. PubMed ID: 9870321
[TBL] [Abstract][Full Text] [Related]
2. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
[TBL] [Abstract][Full Text] [Related]
3. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure.
Kent SJ; Greenberg PD; Hoffman MC; Akridge RE; McElrath MJ
J Immunol; 1997 Jan; 158(2):807-15. PubMed ID: 8992998
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
6. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
[TBL] [Abstract][Full Text] [Related]
7. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.
Johnson RP; Trocha A; Buchanan TM; Walker BD
J Exp Med; 1992 Apr; 175(4):961-71. PubMed ID: 1372650
[TBL] [Abstract][Full Text] [Related]
8. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Kundu SK; Katzenstein D; Moses LE; Merigan TC
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
[TBL] [Abstract][Full Text] [Related]
10. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
McElrath MJ; Corey L; Greenberg PD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
[TBL] [Abstract][Full Text] [Related]
12. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
13. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
Corbet S; Nielsen HV; Vinner L; Lauemoller S; Therrien D; Tang S; Kronborg G; Mathiesen L; Chaplin P; Brunak S; Buus S; Fomsgaard A
J Gen Virol; 2003 Sep; 84(Pt 9):2409-2421. PubMed ID: 12917462
[TBL] [Abstract][Full Text] [Related]
14. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
[TBL] [Abstract][Full Text] [Related]
16. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
[TBL] [Abstract][Full Text] [Related]
17. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
18. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein.
Dupuis M; Kundu SK; Merigan TC
J Immunol; 1995 Aug; 155(4):2232-9. PubMed ID: 7543542
[TBL] [Abstract][Full Text] [Related]
20. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
Achour A; Picard O; Mbika JP; Willer A; Snart R; Bizzini B; Carelli C; Burny A; Zagury D
Vaccine; 1993; 11(7):609-701. PubMed ID: 7688170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
